首页> 外文期刊>Journal of Colloid and Interface Science >lFolic acid-grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy
【24h】

lFolic acid-grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy

机译:洛氏酸接枝牛血清白蛋白装饰石墨烯氧化物:靶向癌症治疗的有效药物载体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Targeting drug carrier systems based on graphene oxide (GO) are of great interest, since it can selectively deliver anticancer drugs to tumor cells, and enhance therapeutic activities with minimized side effects. However, direct grafting target molecules on GO usually results in aggregation of physiological fluid, limiting its biomedical applications. Here, we propose a new strategy to construct targeting GO drug carrier using folic acid grafted bovine serum albumin (FA-BSA) as both the stabilizer and targeting agent. FA-BSA decorated graphene oxide-based nanocomposite (FA-BSA/GO) was fabricated by the physical adsorption of FA-BSA on GO, which was developed as a targeting drug delivery carrier. FA-BSA/GO as the drug carrier was associated with anticancer drug doxorubicin (DOX) through 7C-7T and hydrogen-bond interactions, resulting in high drug loading (up to 437.43 mu g DOX/mg FA-BSA/GO). FA-BSA/GO/DOX systems demonstrated pH responsive and sustained drug release. The hemolysis ratio of FA-BSA/GO was less than 5%, demonstrating its safety as drug carrier for intravenous injection. Moreover, in vitro cell cytotoxicity and cellular uptake analysis suggested that the constructed FA-BSA/GO/DOX nanohybrids could significantly enhance the anticancer activity. The present work has confirmed the potential for fabrication of highly stable and dispersible GO-based targeting delivery systems for efficient cancer therapy. (C) 2016 Elsevier Inc. All rights reserved.
机译:靶向基于石墨烯氧化物(GO)的药物载体系统具有很大的兴趣,因为它可以选择性地将抗癌药物递送给肿瘤细胞,并以最小化的副作用增强治疗活动。然而,直接接枝靶分子通常导致生理流体的聚集,限制其生物医学应用。在这里,我们提出了一种使用叶酸接枝牛血清白蛋白(FA-BSA)作为稳定剂和靶向剂构建靶向去药载体的新策略。 FA-BSA装饰的石墨烯纳米复合材料(FA-BSA / GO)通过FA-BSA的物理吸附,由靶向药物输送载体开发。当药物载体与抗癌药物(DOX)通过7C-7T和氢键相互作用相关,导致高药物负载(高达437.43μgdox / mg fa-bsa / go)相关。 FA-BSA / GO / DOX系统显示PH响应性和持续的药物释放。 Fa-BSA / Go的溶血率小于5%,证明其作为静脉注射药物载体的安全性。此外,体外细胞毒性和细胞摄取分析表明,构建的FA-BSA / GO / DOX纳米胺可以显着提高抗癌活性。目前的工作已经证实了制造高度稳定和可分散的基于GO的靶向递送系统的潜力,以获得有效的癌症治疗。 (c)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号